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background:  There exists a small minority of patients in whom conventional lead placement using the subclavian vein is not feasible due 
to various anatomical considerations. The femoral vein has been previously described as an alternative route for transvenous pacemaker 
placement but the experience is limited. Long term follow up of transfemoral intracardiac defibrillators (ICD’s) and biventricular defibrillators 
(BIVICD’s) have not been previously reported.
Methods:  This study is a single center retrospective systematic clinical review of patient records who received permanent devices using 
the transfemoral route from 2006 to 2013.
results:  A total of seven patients with nonischemic cardiomyopathy (4), complete heart block (2), sudden cardiac arrest (1) and sustained 
ventricular tachycardia (1) were identified (2 BIVICD’s, 2 dual chamber ICD’s, 2 single chamber ICD’s and one dual chamber pacemaker). 
The average age of the patients was 60 (49-83) years. The indications for femoral approach were bilateral subclavian vein occlusion 
and presence of AV fistula or indwelling catheters. The follow up interval averaged 32 (2.3 - 83.4) months for a total of 18 patient-years. 
The average threshold for right atrial, right ventricular and left ventricular pacing at the time of implant and follow up was 1.5 V and 0.8 
V (P=0.06); 0.83 V and 0.86 V (P=0.8) and 1.1 V and 1.375 V respectively. The sensing threshold and impedances of the right atrial and 
right ventricular leads remained stable throughout the follow up period. Defibrillation threshold in ICD patients was successfully tested at 
25 J. During the follow up period only one device related complication in the form of a pocket hematoma resulting in hospitalization was 
successfully drained. No cases of lead dislodgement, re-positioning or deep vein thrombosis were recorded. There were no device related 
deaths during the follow up period; however two patients had expired from unrelated causes.
Conclusion:  From our single center experience, the use of the transfemoral route for device implantation including for resynchronization 
therapy when the subclavian access is inaccessible is safe and effective.
